Does Ketamine Attenuate Depression of Respiratory and Cardiac Functions
Primary Purpose
Congenital Heart Disease, Sedated for Cardiac Catheterization
Status
Completed
Phase
Not Applicable
Locations
Japan
Study Type
Interventional
Intervention
control
Ket10
Ket20
Sponsored by
About this trial
This is an interventional diagnostic trial for Congenital Heart Disease focused on measuring children, sedation, propofol, ketamine
Eligibility Criteria
Inclusion Criteria:
- 7kg-25kg (6mo-10yrs) children who undergo cardiac catheterization
Exclusion Criteria:
- patients who have neurological disease,
- endocrinological disease,
- airway anomaly, who require positive pressure ventilation
Sites / Locations
- Ibaraki Children's Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Sham Comparator
Experimental
Experimental
Arm Label
control
Ket10
Ket20
Arm Description
propofol and saline are administered
ketamine is co-administered with propofol
ketamine is co-administered with porpofol
Outcomes
Primary Outcome Measures
difference of end tidal partial pressure of carbon dioxide between the groups
difference of partial pressure of arterial carbon dioxide between the groups
heart rate change from baseline value
non-invasive blood pressure change from baseline value
Secondary Outcome Measures
movement at topical anesthetic injection
none (no movement or slight movement unnecessary to restrain)
mild (movement necessary to restrain, limited to lower extremities)
moderate (strong movement of lower extremities and movement of upper extremities unvecessary to restrain)
severe (movement necessary to restrain upper extremities and body trunk in addition to lower extremities, or some vacalization)
the number of times that secreted saliva is aspirated by an attending anesthesiologist
Full Information
NCT ID
NCT01501786
First Posted
December 10, 2011
Last Updated
July 28, 2013
Sponsor
Ibaraki Children's Hospital
1. Study Identification
Unique Protocol Identification Number
NCT01501786
Brief Title
Does Ketamine Attenuate Depression of Respiratory and Cardiac Functions
Official Title
The Effect of Small-dose Ketamine on Depression of Respiratory and Cardiac Functions Caused by Propofol in Pediatric Cardiac Catheterization
Study Type
Interventional
2. Study Status
Record Verification Date
July 2013
Overall Recruitment Status
Completed
Study Start Date
January 2012 (undefined)
Primary Completion Date
May 2013 (Actual)
Study Completion Date
May 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ibaraki Children's Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Normal cardiac and respiratory functions should be maintained during pediatric cardiac catheterization. Propofol has become a popular choice for sedation in children, however, it depresses cardiac and respiratory functions. Some investigators reported that ketamine attenuates its depressant effect, but it remains unclear whether ketamine reduces cardiac and respiratory depression caused by propofol in pediatric cardiac catheterization.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Congenital Heart Disease, Sedated for Cardiac Catheterization
Keywords
children, sedation, propofol, ketamine
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
150 (Actual)
8. Arms, Groups, and Interventions
Arm Title
control
Arm Type
Sham Comparator
Arm Description
propofol and saline are administered
Arm Title
Ket10
Arm Type
Experimental
Arm Description
ketamine is co-administered with propofol
Arm Title
Ket20
Arm Type
Experimental
Arm Description
ketamine is co-administered with porpofol
Intervention Type
Drug
Intervention Name(s)
control
Other Intervention Name(s)
saline with propofol
Intervention Description
propofol 8mg/kg/h saline 0.24 ml/kg/h
Intervention Type
Drug
Intervention Name(s)
Ket10
Other Intervention Name(s)
ketamine 10 γ
Intervention Description
propofol 6.4 mg/kg/h ketamine 10 microg/kg/min
Intervention Type
Drug
Intervention Name(s)
Ket20
Other Intervention Name(s)
ketamine 20 γ
Intervention Description
propofol 4.8 mg/kg/h ketamine 20 microg/kg/min
Primary Outcome Measure Information:
Title
difference of end tidal partial pressure of carbon dioxide between the groups
Time Frame
30 and 60 min after anesthetic induction
Title
difference of partial pressure of arterial carbon dioxide between the groups
Time Frame
60 min after anesthetic induction on average
Title
heart rate change from baseline value
Time Frame
30 and 60 min after anesthetic induction
Title
non-invasive blood pressure change from baseline value
Time Frame
30 and 60 min after anesthetic induction
Secondary Outcome Measure Information:
Title
movement at topical anesthetic injection
Description
none (no movement or slight movement unnecessary to restrain)
mild (movement necessary to restrain, limited to lower extremities)
moderate (strong movement of lower extremities and movement of upper extremities unvecessary to restrain)
severe (movement necessary to restrain upper extremities and body trunk in addition to lower extremities, or some vacalization)
Time Frame
20 min after anesthetic induction on average
Title
the number of times that secreted saliva is aspirated by an attending anesthesiologist
Time Frame
From anesthetic induction to termination of anethetics administration, which is not over 2 hours from anesthetic induction
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
10 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
7kg-25kg (6mo-10yrs) children who undergo cardiac catheterization
Exclusion Criteria:
patients who have neurological disease,
endocrinological disease,
airway anomaly, who require positive pressure ventilation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kazuhiko Okuyama, MD
Organizational Affiliation
Ibaraki Children's Hospital
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Yuki Takeda, MD
Organizational Affiliation
Ibaraki Children's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ibaraki Children's Hospital
City
Mito
State/Province
Ibaraki
ZIP/Postal Code
311-4145
Country
Japan
12. IPD Sharing Statement
Learn more about this trial
Does Ketamine Attenuate Depression of Respiratory and Cardiac Functions
We'll reach out to this number within 24 hrs